Dr. Jose Maciel Larios completed a postdoctoral fellowship in a breast oncology/pharmacology lab at the University of Michigan. During his fellowship, Dr. Larios investigated molecular mechanisms of endocrine resistance in hormone receptor-positive breast cancer. He recapitulated newly published mutations in the estrogen receptor gene using breast cancer cell lines as pre-clinical models. Additionally, Dr. Larios also examined mechanisms of resistance to CDK4/6 inhibitors. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. As a transplant hematologist, he would like to explore the role of the bone marrow microenvironment in leukemia progression.
Research and Clinical Interests:
Popular Mechanics It could be a mummy’s curse, but scientists believe it’s a toxic fungal spore that killed people entering tombs in the 1920s and 1970s. José Larios, M.D. , transplant hematologist and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, reviewed a recent study that said this particular fungus could help in targeting and killing leukemia cells. He explained how long it could take to know if this fun...
Patient Power Adult patients with relapsed or refractory large B-cell lymphoma now have access to the FDA-approved drug, brentuximab vedotin (BV). This new approval has extended the use of BV with lenalidomide and rituximab for patients who have had two or more lines of therapy and are ineligible for transplantation. José Larios, M.D. , transplant hematologist and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, expla...
Latinos en Michigan The Barbara Ann Karmanos Cancer Institute welcomes José Larios, M.D. , transplant hematologist and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams, to its team of oncology experts. Dr. Larios specializes in treating leukemia and lymphoma blood cancers, including Hodgkin and non-Hodgkin lymphomas. Read the article in Spanish here .